NATCO PHARMA
Back to Balance Sheet
|
NATCO PHARMA Last 5 Year Total Non-Current Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹-61 Cr | ₹25 Cr | ₹61 Cr | ₹101 Cr | ₹135 Cr |
What is the latest Total Non-Current Liabilities ratio of NATCO PHARMA ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2026 | ₹-61 Cr |
| Mar2025 | ₹25 Cr |
| Mar2024 | ₹61 Cr |
| Mar2023 | ₹101 Cr |
| Mar2022 | ₹135 Cr |
How is Total Non-Current Liabilities of NATCO PHARMA Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹-61 Cr | Negative | |
| Mar2025 | ₹25 Cr | -59.18 | |
| Mar2024 | ₹61 Cr | -39.30 | |
| Mar2023 | ₹101 Cr | -25.61 | |
| Mar2022 | ₹135 Cr | - | |
Compare Total Non-Current Liabilities of peers of NATCO PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NATCO PHARMA | ₹15,045.3 Cr | 3.4% | -2.8% | -5.3% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹444,717.0 Cr | 1% | -3.3% | 13.1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹255,115.0 Cr | 2.6% | 10.8% | 57.3% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹189,613.0 Cr | 2.7% | 0.3% | 39.6% | Stock Analytics | |
| CIPLA | ₹112,876.0 Cr | 2.4% | -1.1% | -12.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹100,395.0 Cr | 2.5% | 0.8% | -8.5% | Stock Analytics | |
NATCO PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NATCO PHARMA | 3.4% |
-2.8% |
-5.3% |
| SENSEX | -0.5% |
-4.8% |
-11% |
You may also like the below Video Courses